<DOC>
	<DOCNO>NCT01605916</DOCNO>
	<brief_summary>The objective study investigate safety tolerability AZD6244 give monotherapy combination docetaxel 2nd line therapy Japanese patient Advanced Solid Malignancies Locally Advanced Metastatic Non-Small Cell Lung Cancer . In addition , pharmacokinetic profile AZD6244 investigate . Following combination regimen dose escalation phase ( Part A ) study additional patient may enrol dose expansion phase ( Part B ) refine safety , tolerability , pharmacokinetics biological activity combination patient population .</brief_summary>
	<brief_title>Investigate Safety Tolerability AZD6244 Monotherapy + Docetaxel Japanese Patients With Advanced Solid Malignancies Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The objective combination therapy part study investigate safety tolerability AZD6244 give combination docetaxel 2nd line therapy Japanese patient Locally Advanced Metastatic Non-Small Cell Lung Cancer ( Stage IIIB-IV ) . In addition , pharmacokinetic profile AZD6244 docetaxel investigate . The objective monotherapy part study investigate safety tolerability AZD6244 give monotherapy Japanese patient advance solid malignancy . In addition , pharmacokinetic profile monotherapy AZD6244 investigate .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients diagnose lung cancer respond prior therapy become worse . Patients overall good general condition . Patients least one lesion accurately assess image . Patients appropriate renal condition confirm test result take part study . Evidence nonchildbearing status woman childbearing potential , postmenopausal status . Patients brain metastasis spinal cord compression . Patients significant abnormal ECG finding . Patients evidence severe uncontrolled systemic disease . The main organ functional test value bone marrow , kidney , liver , etc. , meet standard . Patients know hypersensitivity docetaxel product contain polysorbate 80 . Only monotherapy cohort eligibility criterion Patients advance solid malignancy refractory standard treatment standard therapy exist irrespective stage previous treatment . Patients histologically cytologically confirm advanced solid malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cancer ,</keyword>
	<keyword>Tumour ,</keyword>
	<keyword>Metastatic ,</keyword>
	<keyword>Lung cancer ,</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>